ADAR1 Capital Management LLC Has $1.52 Million Position in Insmed Incorporated (NASDAQ:INSM)

ADAR1 Capital Management LLC grew its holdings in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 504.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,974 shares of the biopharmaceutical company's stock after purchasing an additional 18,340 shares during the quarter. ADAR1 Capital Management LLC's holdings in Insmed were worth $1,517,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Steward Partners Investment Advisory LLC lifted its position in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC lifted its holdings in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management acquired a new stake in Insmed in the 4th quarter worth approximately $47,000. Smartleaf Asset Management LLC boosted its position in Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 411 shares during the period. Finally, Venturi Wealth Management LLC acquired a new position in Insmed during the fourth quarter valued at approximately $86,000.

Insmed Price Performance

Shares of Insmed stock traded up $3.76 during mid-day trading on Friday, reaching $68.57. 1,823,424 shares of the stock were exchanged, compared to its average volume of 2,276,898. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company has a market cap of $12.47 billion, a price-to-earnings ratio of -12.27 and a beta of 1.07. The firm has a 50-day simple moving average of $76.20 and a 200 day simple moving average of $73.64. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. On average, sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. raised their target price on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research note on Friday, February 7th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 target price on shares of Insmed in a report on Wednesday, March 19th. Stifel Nicolaus dropped their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. UBS Group increased their price target on shares of Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Finally, HC Wainwright restated a "buy" rating and set a $90.00 price objective on shares of Insmed in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $94.00.

Insider Activity

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the sale, the insider now owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Martina M.D. Flammer sold 1,384 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $68.72, for a total transaction of $95,108.48. Following the completion of the transaction, the insider now owns 100,165 shares in the company, valued at $6,883,338.80. This represents a 1.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 499,613 shares of company stock worth $39,569,355. 4.60% of the stock is owned by corporate insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.